Investigating Role of Biomarkers in Meningioma Diagnosis Using Liquid Biopsy
Study aims to explore diagnostic potential of specific biomarkers in liquid biopsy samples of patients with meningioma, addressing challenges in current diagnosis methods and potential implications for treatment decisions.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Investigating the role of biomarkers using liquid biopsy in diagnosis for meningiomas Stj. Dr Hasiba Karimi Mentor: Prof. Dr. Mustafa Aziz Hatibo lu 14.03.22
Presentation plan Meningiomas Challenges in Diagnosis & Management Liquid biopsy The Gap in Knowledge Aim of the study Method Results Conclusion
Meningioma The most common primary brain tumor in adults The majority of meningiomas are benign tumors (WHO I) Diagnosed with radiological methods No effective pharmacological intervention has been established to date Differentiation of meningiomas from other malignancies is challenging Imaging may not provide information on the grade of meningiomas
Challenges in Diagnosis Challenges in selecting treatment choice (follow up, surgical resection, Gamma Knife) and extent of tumor resection Only help identify the tumors when they reach a certain size Increasing the risk of malignancy overtime Slow growing tumors and might go undetected for years. Tissue biopsy; for the definitive diagnosis and histological classification of meningioma; Invasive method with effectiveness limited to stage of the tumor detected and the area that s biopsied. Potential morbidity
Liquid biopsy Liquid biopsy is: less invasive more feasible easier to repeat ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/ providing valuable information about the tumor molecular structure and genomic dynamics.
Gap in Knowledge c-MYC, FABP7, GATA4 and MAOB; implicated with meningioma grades using tumor tissue samples; Their roles in diagnosing, staging and prognosis of meningioma is unclear yet. Have not been studied from liquid biopsy samples before.
Aim of the study To identify diagnostic and prognostic potential of c-MYC, FABP7, GATA4 and MAOB in liquid biopsy samples of patients with meningioma.
Materials & Method 20 patients undergoing surgery for meningioma included May 2017 March 2021 Tumor and serum samples from 20 meningioma patients who underwent surgical resection in Bezmialem Vak f university Hospital Stored at -80 C
Materials & Method 15 healthy individuals used for controls. The expression level of FABP7, GATA-4, c-MYC, and MAOB genes were evaluated with real time PCR Patient s clinical data including age, gender, radiological findings, simpson grade, post surgical complication and recurrence were retrospectively collected. GraphPad Prism 3.0 was used for data analysis
DemographicInformation Characteristic Value Cases Total (F/M) 20 (12/8) Median age (range), years 53 (41-75) Histological type, Grade; Atypical/Clear cell, Grade 2 9 patients Transitional,Grade 1 8 patients Angiomatosis,Grade 1 1 patient Fibrous,Grade 1 1 patient Meningothelial,Grade 1 1 patient
Results Comparision of gene expressions in serum samples between control and meningioma pateints p=0.036 P=0.412 p=0.0425 P=0.614
Comparision of gene expressions in serum samples between Control, Grade 1, and Grade 2 meningioma pateints p=0.032 control and grade 2
Comparision of gene expressions in Tumor samples between Grade 1 and Grade 2 meningioma pateints p=0.003 P=0.120 p=0.041 p=0.0310
Conclusion The expression level of GATA-4, c-MYC and MAOB were statistically significant in grade II meningioma tumor samples The expression level of MAOB was statistically significant in grade II serum samples Our results suggested that serum expression of FABP7, GATA4, c-MYC and MAOB gene could be implemented as diagnostic marker for meningiomas Further studies are required ; With larger sample sizes The implementation of biomarkers in evaluating: recurrence probability course of the disease
References 1. What is Meningioma? [Internet]. Meningioma Brain Tumors - Brigham and Women's Hospital. [cited 2020Dec2]. Available from: https://www.brighamandwomens.org/neurosurgery/meningioma 2. Sabedot TS, Malta TM, Snyder J, Walbert T, Lee I, Kalkanis S, et al. Abstract A12: DNA methylation-based liquid biopsy detects primary and recurrent meningioma [Internet]. Clinical Cancer Research. American Association for Cancer Research; 2020 [cited 2020Dec2]. Available from: https://clincancerres.aacrjournals.org/content/26/11_Supplement/A12.abstract 3. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pell E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology [Internet]. Therapeutic advances in medical oncology. SAGE https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116068/ Publications; 2018 [cited 2020Dec2]. Available from: 5. Sareen H;Garrett C;Lynch D;Powter B;Brungs D;Cooper A;Po J;Koh ES;Vessey JY;McKechnie S;Bazina R;Sheridan M;Gelder JV;Darwish B;Jaeger M;Roberts TL;De Souza P;Becker TM; The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients [Internet]. Cancers. U.S. National Library of Medicine; [cited 2020Dec2]. Available from: https://pubmed.ncbi.nlm.nih.gov/32650387/ usage of liquid biopsies in the clinical setting: a systematic review [Internet]. BMC cancer. BioMed Central; 2018 [cited 2020Dec2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935950/ Arneth B. Update on the types and 6. Erkan EP, Str bel T, Dorfer C, Sonntagbauer M, Weinh usel A, Saydam N, et al. Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation [Internet]. Frontiers. Frontiers; 2019 [cited 2020Dec2]. Available from: https://doi.org/10.3389/fonc.2019.01031 7. Ongaratti BR;Silva CB;Trott G;Haag T;Le es CG;Ferreira NP;Oliveira MC;Pereira-Lima JF;. (n.d.). Expression of MERLIN, NDRG2, ERBB2, and c-MYC in Meningiomas: Relationship with tumor grade and recurrence. Retrieved April 03, 2021, from https://pubmed.ncbi.nlm.nih.gov/27007654/ 8. ME;, K. A. W. H. P. C. W. (n.d.). The use of microfluidic technology for cancer applications and liquid biopsy. Micromachines. Retrieved March 4, 2022, from https://pubmed.ncbi.nlm.nih.gov/30424330/ 9. Haddad, A. F., Young, J. S., Kanungo, I., Sudhir, S., Chen, J.-S., Raleigh, D. R., Magill, S. T., McDermott, M. W., & Aghi, M. K. (1AD, January 1). Who grade I meningioma recurrence: Identifying high risk patients using histopathological features and the MIB-1 index. Frontiers. Retrieved March 4, 2022, from https://www.frontiersin.org/articles/10.3389/fonc.2020.01522/full 10. Dunn J;Lenis VP;Hilton DA;Warta R;Herold-Mende C;Hanemann CO;Futschik ME;. (n.d.). Integration and comparison Of Transcriptomic and proteomic data FOR Meningioma. Retrieved March 06, 2021, from https://pubmed.ncbi.nlm.nih.gov/33167358/
Acknowledgment BILSAB Brain tumor research laboratory Dr. Mustafa Aziz Hatibo lu Neurosurgery BILSA Dr. Mustafa Aziz Hatibo lu Kerime Akdur Dr. G ven G nen Ayten akarcan Merve avu o lu Bur e Elbasan Imran Khan,PhD Sadaf Mahfooz, PhD B ra Kara am, RA www.gammaknifeturkey.com gk@bezmialem.edu.tr
